These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 11985363)

  • 1. Antitrust, health care quality, and the courts.
    Hammer PJ; Sage WM
    Columbia Law Rev; 2002 Apr; 102(3):545-649. PubMed ID: 11985363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The legal framework for effective competition.
    Berenson RA; Hastings DA; Kopit WG
    Baxter Health Policy Rev; 1996; 2():235-65. PubMed ID: 11066262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health care reform and competing visions of medical care: antitrust and state provider cooperation legislation.
    Blumstein JF
    Cornell Law Rev; 1994 Sep; 79(6):1459-506. PubMed ID: 10141441
    [No Abstract]   [Full Text] [Related]  

  • 5. A conflict of interest: why peer review committees need heightened scrutiny under federal antitrust law.
    Rakestraw E
    J Leg Med; 2009; 30(4):563-78. PubMed ID: 19953408
    [No Abstract]   [Full Text] [Related]  

  • 6. Understanding antitrust: focus on the relevant market.
    Enders RJ
    Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are you violating antitrust laws?
    Saylor LJ
    Mich Hosp; 1992; 28(1):29-33. PubMed ID: 10116190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The development of preferred provider organizations and its antitrust implications.
    Maram BS
    J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The physician self-referral dilemma: enforcing antitrust law as a solution.
    Mathews JE
    Am J Law Med; 1993; 19(4):523-46. PubMed ID: 7942867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of recent antitrust issues affecting specialty practice: is dermatology immune?
    Gibofsky A
    Semin Cutan Med Surg; 2005 Sep; 24(3):137-43. PubMed ID: 16202949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accountable Care Organizations and Antitrust Enforcement: Promoting Competition and Innovation.
    Feinstein DL; Kuhlmann P; Mucchetti PJ
    J Health Polit Policy Law; 2015 Aug; 40(4):875-86. PubMed ID: 26124309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emerging trend of corporate liability: courts' uneven treatment of hospital standards leaves hospitals uncertain and exposed.
    Rutchik DH
    Spec Law Dig Health Care Law; 1995 Feb; (192):9-45. PubMed ID: 10144587
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost containment in the health care field and the antitrust laws.
    Shapiro DI
    Am J Law Med; 1982; 7(4):425-35. PubMed ID: 7102679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hospital mergers: the shift from federal antitrust enforcement to state regulation.
    Blackstone EA; Fuhr JP
    J Health Law; 2000; 33(1):103-27. PubMed ID: 10788226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitrust. Is quality review in jeopardy?
    Pollner F
    Med World News; 1988 Jun; 29(12):34-6, 38, 43-7. PubMed ID: 10287973
    [No Abstract]   [Full Text] [Related]  

  • 17. Monopoly, monopsony, and market definition: an antitrust perspective on market concentration among health insurers.
    Hyman DA; Kovacic WE
    Health Aff (Millwood); 2004; 23(6):25-8. PubMed ID: 15537581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five reasons why health care quality research hasn't affected competition law and policy.
    Hyman DA
    Int J Health Care Finance Econ; 2004 Jun; 4(2):159-66. PubMed ID: 15211104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic and antitrust analysis of the distribution of medical products.
    Celnicker AC
    Am J Law Med; 1990; 16(4):499-523. PubMed ID: 2102059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Applying antitrust law to nonprofit healthcare entities: arguments for a greater attention to detail.
    Swearingen MJ
    J Health Law; 2000; 33(1):57-101. PubMed ID: 10788231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.